Protect the Immunosuppressed Patient: Prophylaxis and Late Acute GVHD

Protect the Immunosuppressed Patient: Prophylaxis and Late Acute GVHD

A 15-minute microlearning activity on extending letermovir prophylaxis through Day 200 in high-risk patients, providing mold-active antifungal prophylaxis during high-dose GVHD immunosuppression, and recognizing late acute GVHD presentations.

Price
Free
Provider
IQ Apparatus
Release date
August 17, 2026
Expires
July 22, 2027
Start activity

Credits

Learning objectives

Upon completion, participants should be able to:

  1. Apply current aGVHD staging, grading, and treatment-response criteria to assess disease severity and identify steroid-refractory disease.
  2. Evaluate clinical and biomarker-based risk-stratification tools to support aGVHD prognostication while recognizing their limitations in guiding routine treatment decisions.
  3. Determine when treatment escalation is appropriate for patients with steroid-refractory aGVHD based on current criteria and guideline recommendations.

Faculty